Cognitive Enhancement

DNSP-11

Dopamine Neuron Stimulating Peptide-11

GDNF-derived peptide targeting Parkinson's disease

DNSP-11 is an 11-amino-acid peptide derived from the proprotein region of GDNF (Glial Cell Line-Derived Neurotrophic Factor), developed as a potential treatment for Parkinson's disease.

DNS
💉

Admin routes

Intranasal, Intracerebroventricular (research)

🔬

Popularity

Niche

✅

Side effects

Generally mild

🏪

AU vendors

0 rated

✓Key benefits

1Preserves dopaminergic neurons in Parkinson's disease models
2Small enough for potential intranasal delivery to the brain
3Distinct mechanism from full-length GDNF

📈What to expect

1
N/A

No human dosing data. Animal studies showed neuroprotection over 2-4 weeks.

Based on community reports and published research. Individual results vary significantly.

💊Dosing protocols

Research reference (animal studies)

Dose

Varies by study

Frequency

Daily in published protocols

Duration

2-4 weeks in animal studies

Dosing information is sourced from published research and community protocols. This is not a recommendation. Consult a healthcare professional.

Research status|Preclinical - animal models of Parkinson's disease

Overview

DNSP-11 was discovered by researchers at the University of Kentucky who identified that the pro-region of GDNF (the part normally cleaved off during processing) contains biologically active sequences. DNSP-11 specifically promotes the survival and function of dopaminergic neurons without requiring the full GDNF protein, which is too large to cross the blood-brain barrier easily. In animal models of Parkinson's disease, DNSP-11 preserved dopamine neuron function and improved motor outcomes. Its small size makes it a more practical therapeutic candidate than full-length GDNF.

⚙️How it works

DNSP-11 promotes dopaminergic neuron survival through mechanisms distinct from mature GDNF. While GDNF signals through the GFRalpha1/RET receptor complex, DNSP-11 appears to work through a different pathway. It increases dopamine levels, preserves tyrosine hydroxylase-positive neurons, and reduces oxidative stress in the substantia nigra. The exact receptor target is still being characterised.

⚡Side effects

No human safety data available
moderateRare

📅Research history

2010

Bradley et al. publish identification and characterisation of DNSP-11

References

  1. [1]Bradley LH, et al. 'Dopamine neuron stimulating actions of a GDNF propeptide.' PLoS ONE, 2010.

Frequently asked questions

Related peptides

Cerebrolysin

Cognitive Enhancement

Neurotrophic peptide mixture with 50+ years of clinical use

0 rated vendors

Cortexin

Cognitive Enhancement

Russian neuropeptide complex used clinically for decades

0 rated vendors

Semax

Cognitive Enhancement

The Russian nootropic peptide with 30 years of clinical use

3 rated vendors

9-Me-BC

Cognitive Enhancement

The dopaminergic nootropic from beta-carboline research

0 rated vendors

Community experiences

Share your experience with DNSP-11. Effects, side effects, protocol details - help others make informed decisions.

Write a review

Rating:

No community reviews yet. Be the first to share your experience with DNSP-11.

Need to calculate your dose?

Use our free reconstitution calculator to work out syringe units for DNSP-11.

Open Calculator

Found this useful?

Share this guide

Disclaimer: This guide is for educational and informational purposes only. It is not medical advice. The dosing protocols listed are sourced from published research and community reports and do not constitute a recommendation. Always consult a qualified healthcare professional before using any peptide. Australian regulations classify many peptides as Schedule 4 (prescription-only) substances. Check current TGA guidelines before purchasing.